Welcome
Our mission is to bring a broad range of potentially transformative medicines to patients in Greater China.
We recently launched with a $72M Series A co-led by Cormorant Asset Management LP and Hansoh Pharmaceutical Group Company Limited. Read the press-release here.
Our website will be up shortly.